Cell therapy (CAR-T) · Kills target cells, directed at NKG2D ligands · developed by CytoMed Therapeutics Pte
Adoptive cell transfer of haploidentical or allogeneic gamma delta T cells grafted with a chimeric antigen receptor targeting NKG2D ligands (CTM-N2D). The engineered cells are designed to recognize and kill NKG2D ligand-expressing tumor cells. It is studied in colorectal cancer, triple negative breast cancer, sarcoma, nasopharyngeal carcinoma, prostate cancer and gastric cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04107142 | Phase 1 | Colorectal Cancer | Unknown | GDTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerGastric CancerNasopharyngeal CarcinomaProstate CancerSarcomaTriple Negative Breast Cancer
Updated Oct 11, 2026. Something wrong or missing? Report it on the GDTC page.
See GDTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GDTC catalysts and pipeline →